Flavio G. Vincenti, MD

Flavio G. Vincenti, MD, is a clinical professor of medicine and surgery in the Department of Medicine and the Kidney Transplant Service at the University of California, San Francisco (UCSF).

Dr Vincenti has participated in more than 15,000 kidney transplants at UCSF over a 50-year period. Along with William Amend, MD, he cofounded Transplant Nephrology at UCSF.

He has extensive experience in clinical trials, especially those involving novel drug treatments for transplant recipients. Dr Vincenti was the principal investigator (PI) for multiple studies of agents that ultimately received US Food and Drug Administration approval, including tacrolimus, daclizumab, and belatacept. He also was the PI for numerous studies involving novel biologics to induce a tolerant state, including efalizumab (anti-CD11a), alefacept (anti-CD2), lulizumab (anti-CD28), iscalimab (anti-CD40), bleselumab (anti-CD40), and dazodalibep (anti-CD40L). Additionally, Dr Vincenti was the PI for the first clinical trial using dual costimulation blockade as sole immunoprophylaxis in renal transplantation, for the Clinical Trials in Organ Transplantation grant that was first to use cellular therapy (regulatory T cells) to regulate inflammation in the graft, and for the only randomized trial to demonstrate the effect of tocilizumab on regulatory T cells in subclinical inflammation in the renal allograft. Moreover, he designed and was the PI for the first trial studying the anti-CD38 monoclonal antibody isatuximab for desensitization. He is also the PI for the first multicenter trial of vonsetamig, a BCMAxCD3 antibody, for desensitization. Finally, Dr Vincenti is currently the PI for an Immune Tolerance Network–sponsored trial combining belatacept and daratumumab to desensitize highly sensitized patients.

Dr Vincenti has published more than 270 peer-reviewed articles. He is past president of the American Society of Transplantation (AST) and received the AST Lifetime Achievement Award in 2012.